Clinical Trials on Precursor Cell Lymphoblastic Leukemia-Lymphoma

Total 7374 results

Therapeutic Advances in Childhood Leukemia Consortium

Terminated

A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

Acute Lymphoblastic Leukemia | Precursor B-Cell Lymphoblastic Leukemia | Precursor T-Cell Lymphoblastic Leukemia

United States, Australia
Sanofi

Terminated

Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia (ISLAY)

T-cell Type Acute Leukemia-Precursor | T-lymphoblastic Lymphoma/Leukaemia

Hungary, United States, Finland, France, Italy, Lithuania, Russian Federation
Mundipharma Research Limited
Innovative Therapies For Children with Cancer Consortium

Terminated

Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma. (BCX1777-108)

Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia | B-cell Precursor Acute Lymphoblastic Leukaemia | T-cell Non-Hodgkin's Lymphoma

Czech Republic, Austria, France, Germany, Italy, United Kingdom
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART B)

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic...

Netherlands
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART C)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART A)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies (HEM-iSMART D)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
Bristol-Myers Squibb

Completed

Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Lymphoblastic Leukemia, Acute T-cell | Precursor T-Cell Lymphoblastic Lymphoma

United States, France, Germany
Shanghai Children's Medical Center
Miltenyi Biomedicine GmbH

Unknown

MB-CART19.1 in Patients With R/R ALL

Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory
Asan Medical Center

Terminated

Acute Lymphoblastic Leukemia Registry at Asan Medical Center

Lymphoblastic Lymphoma | Leukemia, Biphenotypic, Acute | Leukemia, Acute Lymphoblastic | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Precursor B-Cell Lymphoblastic Leukemia

Korea, Republic of
Pfizer

Completed

A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients

Leukemia | Precursor b-Cell Lymphoblastic Leukemia-Lymphoma | ACUTE LYMPHOBLASTIC LEUKEMIA

United States, Spain, Taiwan, Singapore, India, Hungary, Turkey, Poland
Wugen, Inc.

Recruiting

A Phase 1/2 Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

Lymphoblastic Lymphoma | T-cell Acute Lymphoblastic Leukemia

United States, Australia, Netherlands, France
Beam Therapeutics Inc.

Recruiting

A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)

Lymphoblastic Lymphoma | Lymphoblastic Leukemia | T-Cell Lymphoblastic Leukemia/Lymphoma

United States
BioCryst Pharmaceuticals

Terminated

Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens

Lymphoma | Leukemia

United States
920th Hospital of Joint Logistics Support Force...

Withdrawn

A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL

T-lymphoblastic Lymphoma | T-cell Acute Lymphoblastic Leukemia

China
Beijing Boren Hospital

Recruiting

Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma

T-Cell Acute Lymphoblastic Leukemia/Lymphoma

China
First Affiliated Hospital of Zhejiang University

Recruiting

Modified TBF Regimen as Conditioning Regimen Prior to Allo-HSCT for T-ALL/LBL

Cytarabine+Thiotepa + Fludarabine + Busulfan | T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma

China
Bambino Gesù Hospital and Research Institute

Not yet recruiting

CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL (CD7-CAR01)

T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Wugen, Inc.

Enrolling by invitation

A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007

T-cell Acute Lymphoblastic Leukemia | T-cell Lymphoblastic Lymphoma

United States, Australia
Ehab L Atallah

Recruiting

XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia

Acute Myeloid Leukemia | T Cell Lymphoblastic Lymphoma | T Cell Acute Lymphoblastic Leukemia

United States
OneChain Immunotherapeutics
Hospital Clinic of Barcelona; Hospital Sant Joan de Deu; BioClever 2005 S.L.

Recruiting

Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL (CARxALL)

T-cell Acute Lymphoblastic Leukemia | Lymphoblastic T-Cell Lymphoma

Spain
New York Medical College

Recruiting

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma (ALLO-T-DART)

T-cell Acute Lymphoblastic Leukemia | T-Cell Acute Lymphoblastic Lymphoma

United States
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

T-cell Acute Lymphoblastic Leukemia/Lymphoma

China
Hebei Senlang Biotechnology Inc., Ltd.

Completed

Cell Therapy for CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD7-Specific CAR-T Cells

T-cell Acute Lymphoblastic Leukemia/Lymphoma

China
Eli Lilly and Company

Completed

A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

T-cell Acute Lymphoblastic Leukemia | T-cell Lymphoblastic Lymphoma

United States, Germany, Israel, France, Italy
Zhejiang University

Recruiting

Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas

T Lymphoblastic Leukemia/Lymphoma

China
St. Jude Children's Research Hospital
Novartis Pharmaceuticals; Spectrum Pharmaceuticals, Inc

Terminated

Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Acute Lymphoblastic Leukemia | Leukemia, B-Cell | Leukemia, T-Cell | Lymphoma, Non-Hodgkin's

United States
Therapeutic Advances in Childhood Leukemia Consortium
GlaxoSmithKline; Novartis

Terminated

Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

Relapsed T-Cell Acute Lymphoblastic Leukemia | Relapsed T-Cell Lymphoblastic Lymphoma

United States, France, Canada, Australia, Austria, Italy, Netherlands
Shenzhen Geno-Immune Medical Institute

Recruiting

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

T Acute Lymphoblastic Leukemia | T Lymphoblastic Lymphoma

United States, Canada, Australia, New Zealand, Switzerland
Washington University School of Medicine
National Cancer Institute (NCI); National Institutes of Health (NIH); The Leukemia...

Terminated

BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma

T-Acute Lymphoblastic Leukemia | Adult T Lymphoblastic Lymphoma

United States
Fundamenta Therapeutics, Ltd.
The First Affiliated Hospital of University of Science and Technology of...

Recruiting

Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies

T-Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma | T-cell Acute Lymphoblastic Lymphoma

China
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA)

T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | T-non-Hodgkin Lymphoma

United States
Min Xiang

Unknown

RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL

T-lymphoblastic Lymphoma | T Acute Lymphoblastic Leukemia

China
Millennium Pharmaceuticals, Inc.

Withdrawn

Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)

Precursor Cell Lymphoblastic Leukemia-lymphoma

Spain, United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Precursor Cell Lymphoblastic Leukemia-Lymphoma

United States, United Kingdom, France, Sweden, Germany, Spain, Italy, Belgium, Israel, Netherlands
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances

T-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma | T-cell Acute Lymphoblastic Lymphoma

China
Nicola Goekbuget

Recruiting

Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL

Precursor Cell Lymphoblastic Leukemia

Germany
National Cancer Institute (NCI)

Not yet recruiting

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

T Acute Lymphoblastic Leukemia | T Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

T Acute Lymphoblastic Leukemia | T Lymphoblastic Lymphoma

United States
GlaxoSmithKline

Completed

Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma

Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic

Japan
Shenzhen Geno-Immune Medical Institute

Recruiting

NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL

T-Cell Acute Lymphoblastic Leukemia

China
Beijing Boren Hospital

Recruiting

Donor-Derived CD5 CAR T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia

T-Cell Acute Lymphoblastic Leukemia

China
Shanghai Tong Ren Hospital
Gracell Biotechnology Ltd.

Unknown

CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies

B-cell Lymphoma | B-cell Malignancy | B-Cell Acute Lymphoblastic Leukaemia

China
Peking University Third Hospital

Not yet recruiting

the Efficacy and Safety of CLAE in R/R T-ALL/LBL

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...

Recruiting

Universal 4SCAR7U Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
M.D. Anderson Cancer Center
Jazz Pharmaceuticals

Terminated

Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Lymphoma | Leukemia | Lymphoblastic Lymphoma | Precursor-B Acute Lymphoblastic Leukemia

United States
Xuanwu Hospital, Beijing
Baoding Children's Hospital

Recruiting

CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia

T-cell Acute Lymphoblastic Leukemia

China
The First Affiliated Hospital of Soochow University
Northern Jiangsu Province People's Hospital; The Second People's Hospital of... and other collaborators

Recruiting

Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients

Recruiting | T-cell Acute Lymphoblastic Leukemia

China
Region Örebro County

Completed

Hyper-CVAD Treatment of Adult T-cell Acute Lymphoblastic Leukemia in Sweden.

T-cell Acute Lymphoblastic Leukemia

Sweden

Clinical Trials on Precursor Cell Lymphoblastic Leukemia-Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations